Literature DB >> 19861993

Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.

John F Seymour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19861993     DOI： 10.1038/nrclinonc.2009.159

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

2.  Rituximab for follicular non-Hodgkin lymphoma.

Authors:  Elangovan Gajraj; Helen Chung; Carole Longson; Andrew Stevens
Journal:  Lancet Oncol       Date:  2008-03-03       Impact factor: 41.316

3.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

4.  Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors.

Authors:  W P Steward; D Crowther; L J McWilliam; J M Jones; D P Deakin; I D Todd; G Blackledge; J Wagstaff; J H Scarffe; M Harris
Journal:  Cancer       Date:  1988-02-01       Impact factor: 6.860

5.  Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.

Authors:  John D Hainsworth; Sharlene Litchy; Don W Shaffer; Van L Lackey; Manuel Grimaldi; F Anthony Greco
Journal:  J Clin Oncol       Date:  2005-01-18       Impact factor: 44.544

6.  Meta-analysis to evaluate the role of interferon in follicular lymphoma.

Authors:  A Z S Rohatiner; W M Gregory; B Peterson; E Borden; P Solal-Celigny; A Hagenbeek; R I Fisher; M Unterhalt; R Arranz; T Chisesi; A Aviles; T A Lister
Journal:  J Clin Oncol       Date:  2005-01-31       Impact factor: 44.544

7.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

Review 8.  Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Authors:  Liat Vidal; Anat Gafter-Gvili; Leonard Leibovici; Martin Dreyling; Michele Ghielmini; Shu-Fang Hsu Schmitz; Amos Cohen; Ofer Shpilberg
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

9.  The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma.

Authors:  E Z Ezdinli; D P Harrington; O Kucuk; M W Silverstein; J Anderson; M J O'Connell
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

10.  Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Authors:  Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  10 in total
  1 in total

1.  Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Authors:  M S Czuczman; J P Leonard; S Jung; J L Johnson; E D Hsi; J C Byrd; B D Cheson
Journal:  Ann Oncol       Date:  2012-02-22       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.